Imara-Logo-Color-RGB.jpg
Imara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
June 04, 2021 07:00 ET | Imara, Inc.
Oral presentation provides final results from 93-patient Phase 2a trial and additional interim data from open label extension trial Imara to host conference call and live webcast on June 11, 2021 at...
Imara-Logo-Color-RGB.jpg
Imara Reports First Quarter 2021 Financial Results and Business Highlights
May 11, 2021 07:00 ET | Imara, Inc.
On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021 Completed enrollment in the...
Imara-Logo-Color-RGB.jpg
Imara to Webcast Conference Call of First Quarter 2021 Financial Results and Business Highlights
May 04, 2021 07:00 ET | Imara, Inc.
BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
FBI LOGO TM.png
Sickle Cell Disease Treatment Market to Exhibit a CAGR of 18.5% and Reach USD 7.71 Billion by 2027; FDA Approval for Emmaus’s Endari to Aid Development, states Fortune Business Insights™
January 20, 2021 08:56 ET | Fortune Business Insights
Pune, India, Jan. 20, 2021 (GLOBE NEWSWIRE) -- The global sickle cell disease treatment market size is expected to reach USD 7.71 billion in 2027, exhibiting a CAGR of 18.5% during the forecast...
Imara-Logo-Color-RGB.jpg
Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory
November 17, 2020 07:00 ET | Imara, Inc.
BOSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
OPEN SANS HH STACKED_2.jpg
New Research Reveals Gazelle Diagnostic Device Outperformed Rapid Diagnostic Test for P. Vivax Malaria, Detected Challenging Types of Malaria, and Provided Affordable Sickle Cell Disease Detection
November 16, 2020 16:10 ET | Hemex Health
PORTLAND, Ore., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Hemex Health, an innovator in point-of-care diagnostic technologies, announced today that researchers will present five scientific posters at the...
OPEN SANS HH STACKED_2.jpg
New Research Shows Gazelle Diagnostic Device Outperformed Rapid Diagnostic Test for P. Vivax Malaria, Detected Challenging Types of Malaria, and Provided Accurate Sickle Cell Disease Detection
November 15, 2020 14:00 ET | Hemex Health
PORTLAND, Ore., Nov. 15, 2020 (GLOBE NEWSWIRE) -- Hemex Health, an innovator in point-of-care diagnostic technologies, announced today that researchers will present five scientific posters at the...
Imara-Logo-Color-RGB.jpg
Imara Reports Third Quarter 2020 Financial Results and Business Highlights
November 05, 2020 07:00 ET | Imara, Inc.
Patient Dosing Underway in Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia IMR-687 granted Orphan Drug designation from European Commission for sickle cell disease ...
22157.jpg
$397.79 Millions Sickle Cell Anemia Testing and Screening Markets, 2027
October 29, 2020 07:53 ET | Research and Markets
Dublin, Oct. 29, 2020 (GLOBE NEWSWIRE) -- The "Sickle Cell Anemia Testing and Screening - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering. Global...
Imara-Logo-Color-RGB.jpg
Imara to Webcast Conference Call of Third Quarter Financial Results
October 29, 2020 07:00 ET | Imara, Inc.
BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...